Insider · CIK 0001854073
Vensana Capital I GP, LLC
Files at SGP (SpyGlass Pharma, Inc.). First filing Feb 10, 2026, latest Feb 10, 2026.
In brief
Vensana Capital I GP, LLC files SEC Form 4 as 10% owner at SGP (SpyGlass Pharma, Inc.). Since Feb 10, 2026, Vensana Capital I GP, LLC has reported 1 open-market buy worth $2.6M and 0 open-market sells worth $0, the latest filed on Feb 10, 2026.
A track record needs three past buys with six months of prices behind them; Vensana Capital I GP, LLC has 0, so none is measured yet.
The newest scored trade: bought $2.6M of SGP on Feb 9, 2026, filed Feb 10, 2026, scored 50 (moderate). In the last 12 months: 1 buy worth $2.6M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SGP: SpyGlass Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 50Moderate | SpyGlass Pharma, Inc. | $2.6M 165,000 shares | +5% | - |
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See footnote | +1,690,230 | - | - | 1,690,230 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See footnote | +548,067 | - | - | 2,238,297 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See footnote | +548,067 | - | - | 2,786,364 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Common Stockindirect: See footnote | +359,255 | - | - | 3,145,619 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | POpen-market purchase Common Stockindirect: See footnote | +165,000 | $16.00 | $2.6M | 3,310,619 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series B Preferred Stockderivativeindirect: See Footnote | -9,689,922 | - | - | 0 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-1 Preferred Stockderivativeindirect: See Footnote | -3,142,015 | - | - | 0 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series C-2 Preferred Stockderivativeindirect: See Footnote | -3,142,015 | - | - | 0 | Feb 10, 2026 |
| Feb 9, 2026 | SGP SpyGlass Pharma, Inc. | CConversion Series D Preferred Stockderivativeindirect: See Footnote | -2,059,573 | - | - | 0 | Feb 10, 2026 |
Questions about Vensana Capital I GP, LLC
Answered from the filings on this page, as of the latest one.
Is Vensana Capital I GP, LLC buying or selling?
In the last 12 months Vensana Capital I GP, LLC reported 1 open-market buy worth $2.6M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $2.6M of SGP on Feb 9, 2026. Grants, option exercises and tax withholding are not counted.
How did Vensana Capital I GP, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Vensana Capital I GP, LLC has 0.
Where does Vensana Capital I GP, LLC file Form 4?
Vensana Capital I GP, LLC has filed Form 4 at SGP (SpyGlass Pharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.